Compassionate Care Center of New York Announces Formation; Application for Medical Cannabis License

CARLE PLACE, N.Y., May 27, 2015 /PRNewswire/ -- Compassionate Care Center of New York™ (CCCNY™), a leading biopharmaceutical company applying to become one of five registered organizations authorized in New York State to serve the condition-specific palliative needs of qualifying patients with safe and accessible pharmaceutical-grade therapeutics derived from the cannabis plant, has announced the formation of a leadership team consisting of world-renowned medical, regulatory and law enforcement experts, including Gastroenterologist, Dr. Larry I. Good, former Executive Vice President and Vice Chairman of CVS Corporation, Jerald Politzer, former New York State prosecutor, Richard W. Lerner, Esq., leading medical cannabis PTSD researcher, Dr. Suzanne Sisley, regulatory affairs expert, Dr. Bruce Burnett, former Chief Security Officer of the Port Authority of New York and New Jersey, Joseph Dunne, and former NYPD Chief of Department, Philip Banks III.

"CCCNY will serve as a vital resource for qualifying patients in New York in need of palliative care. By assembling a world-class team of cultivators, medical experts and researchers, along with New York State's top two highest ranking police officers to retire in 2014, and the former Executive Vice President and Vice Chairman of CVS Corporation, we will be able to provide organic pharmaceutical-grade whole-plant extracts, with consistent cannabinoid profiles, at our Compassionate Care Centers throughout the State -- built to function like pharmacies, but equipped with the most state-of-the-art security available," said Dr. Good, Chief Executive Officer of CCCNY. "By leveraging research and patient data conducted by our domestic and international partners, we will offer qualifying patients in New York State the most effective varieties of medical cannabis in the world to treat each of the 10 approved serious conditions." 

The CCCNY leadership team includes:                                                     

• Dr. Larry I. Good, M.D., F.A.C.G., Chief Executive Officer - Former Chief, Division of Gastroenterology, South Nassau Communities Hospital and Former CEO, Good Pharmaceuticals.
• Jerald Politzer, President & Chief Operating Officer - Former Executive Vice President and Vice Chairman of CVS Corporation, former CEO of Loehmann's, former President of Value City Department Stores, former Chairman and CEO with Salant Corporation, former President and CEO of G. Fox Stores, and former CEO of Filene's Basement.
• Richard W. Lerner, Esq., Executive Vice President - Former Nassau County Assistant District Attorney with more than 40 years of legal experience, and special counsel to the New York State Troopers and half a dozen other law enforcement agencies.
• Dr. Suzanne Sisley, M.D., Chief Medical Officer - Global pioneer in medical cannabis research on PTSD, Principal investigator of the only randomized controlled trial in the world looking at the whole cannabis plant for the treatment of PTSD.
• Dr. Bruce Burnett, Ph.D., Chief Science Officer - VP of Compliance, Regulatory & Medical Affairs at Entera Health, Inc., Former Director of Medical Education & Scientific /Regulatory Affairs at Primus Pharmaceuticals, Inc.
• Philip Banks III, Chief Security Officer - Former NYPD Chief of Department and Chief of Community Affairs.
• Joseph Dunne, Senior Security Adviser - Former Port Authority of New York and New Jersey's  Chief Security Officer.

CCCNY's focus is its proprietary varieties of medical cannabis that carry high levels of cannabidiol (CBD), the non-psychoactive component of the cannabis plant, which has the most medicinal benefits. The cannabinoid ratios of CCCNY's varieties of medical cannabis are recognized by the leading researchers in the industry to be the best products on the market for alleviating symptoms across a range of serious conditions, including Crohn's disease, cancer, Parkinson disease, multiple sclerosis and epilepsy. One of the varieties of medical cannabis which CCCNY holds the exclusive license to in New York State is Haleigh's Hope,™ a nationally renowned variety of medical cannabis which has been instrumental in treating pediatric epilepsy. Haleigh's Hope contains among the highest levels of CBD in the world, while still maintaining an extremely low, but therapeutic, level of tetrahydrocannabinol (THC), incapable of producing a "high".

Gov. Nathan Deal of Georgia last month signed Haleigh's Hope Act, a bill which will legalize low-THC cannabis oil for certain "medication-resistant epilepsies," while creating an infrastructure, registration process and research program for the drug. The face of the bill is Haleigh Cox, a child from Georgia who was having hundreds of seizures a day. A week after hearing a doctor's diagnosis that Haleigh might not live another three months, Haleigh's mother, Janea Cox, packed up and moved to Colorado Springs with her daughter, who immediately started a regimen of Haleigh's Hope cannabis oil. In a March 2014 interview, Cox said, "Now she's thriving, she's healthy, she's happy, and they're absolutely shocked at the difference. So I think we've turned some nonbelievers into believers of cannabis oil."

Compassionate Care Center of New York
Compassionate Care Center of New York™ (CCCNY™) is a leading biopharmaceutical company applying for one of five medical cannabis registrations in New York State. CCCNY holds the exclusive license for New York State for Haleigh's Hope,™ a nationally renowned variety of medical cannabis that has shown to effectively address all forms epilepsy and other neurological disorders. CCCNY will be in an unmatched position to provide the most consistent and effective medical cannabis-derived products to qualifying patients throughout New York State suffering from severe debilitating or life-threatening conditions.

SOURCE Compassionate Care Center of New York